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Abstract
Background: Immunotherapy has been widely used in the treatment of several solid and hematologic malignancies.
Checkpoint inhibitors have been the forefront of cancer immunotherapy in recent years. Cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4) and programmed cell death 1 (PD-1) pathway are the prototypic checkpoint targets for immunotherapy.
When combined, CTLA-4 and PD-1 checkpoint inhibitors work synergistically, but with increased probability of toxicity. The
following case represents an unusual adverse effect of combined treatment with ipilimumab and nivolumab used for
treatment of metastatic melanoma.
Case presentation: A 43-year-old woman with metastatic melanoma presented with severe generalized
weakness and fatigue. She has received two cycles of ipilimumab and nivolumab, last administered 3 weeks
prior to her presentation. Initial investigations revealed severe anemia with appropriate reticulocytosis, severely
elevated lactate dehydrogenase, undetectable haptoglobin level and positive direct coombs test. Patient was
diagnosed with severe autoimmune hemolytic anemia secondary to ipilimumab and nivolumab. She was
successfully treated with high dose steroids and rituximab.
Conclusions: In our case, we present a rare but serious adverse effect of immunotherapy. We illustrate the clinical
presentation and management of immunotherapy associated autoimmune hemolytic anemia. Immunotherapy has
revolutionized the treatment of many malignant conditions; therefore, it is imperative for health care professionals
caring for cancer patient to be familiar with the adverse effects of immunotherapy, which allow for early recognition
and management of these potentially lethal side effects.
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Background
Immunotherapy has been widely used in the treatment of
several solid and hematologic malignancies [1]. It has led
to paradigm shift in management of advanced cancers
with potential for long-term and durable responses [2].
There are several immunotherapy agents approved for use
in oncology practice and many others under investigation
including chimeric antigen receptor T-cells (CAR T-cells),
use of checkpoint inhibitors, interleukin therapy, oncolytic
viruses and vaccines. Checkpoint inhibitors have been the
forefront of cancer immunotherapy in recent years. Their
use have revolutionized the treatment of various
malignancies including melanoma, head and neck cancers,
lung cancer, renal cell carcinoma, bladder cancer and
Hodgkin’s lymphoma. Endogenous immune checkpoints
terminate immune response after antigen activation [3].
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
and programmed cell death 1 (PD-1) pathway are the two
prototypic checkpoint targets for immunotherapy. CTLA-
4 and PD-1 checkpoint inhibitors also work synergistically
[4] which enhances their efficacy, but with increase risk of
adverse effects as well. The following case represents an
unusual adverse effect of combined treatment with ipili-
mumab and nivolumab used for treatment of metastatic
melanoma.
Case presentation
A 43-year-old woman with history of metastatic melanoma
presented to emergency room with severe fatigue. Patient
stated that she started having generalized weakness and
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shortness of breath 2 weeks ago. She denied any fever,
cough, chest pain or any bleeding episodes. Her history was
significant for recently diagnosed metastatic melanoma to
brain, liver and right iliac lymph node. B-raf and c-kit mu-
tations were negative. After completing a course of whole
brain radiation therapy, she was started on immunotherapy
using ipilimumab and nivolumab. She received two cycles
of treatment with the last treatment given 3 weeks prior to
presentation. Her medical history was significant for
hypothyroidism and 20 pack-year smoking. She had signifi-
cant family history of melanoma in multiple relatives as
well. Her medications include hydrocodone, acetamino-
phen, dexamethasone 4 mg three times a day, levetiracetam
and levothyroxine; none of them was recently introduced.
She denied using any over-the-counter medications or
supplements. Physical examination was unremarkable
except for obesity.
Initial laboratory investigations (Table 1) showed white
cell count of 8200/mm3, hemoglobin of 5.6 gm/dL, plate-
let count of 122,000/mm3 and reticulocyte count of 6.5%
(absolute reticulocyte count of 0.11 million/mm3). Further
work up revealed lactate dehydrogenase of 1406 IU/L (ref-
erence normal value: 240 IU/L), total bilirubin of 1.5 mg/
dL, haptoglobin of < 10 mg/dL, creatinine of 0.7 mg/dL
and positive direct coombs test (Positive for both anti-Ig
G and anti-complement 3d). Peripheral smear revealed
several spherocytes and multiple polychromatic cells. No
schistocytes were present on peripheral smear.
Patient was diagnosed with autoimmune hemolytic
anemia (AIHA) secondary to immunotherapy with ipili-
mumab and nivolumab. She was given multiple blood
transfusions and started on pulse dose steroids using
1000 mg of intravenous methylprednisolone daily for
3 days. She was then transitioned to oral prednisone
1 mg/kg daily and was tapered over a period of several
weeks. Her hematological parameters improved gradually
over a period of 2 months. Immunotherapy was held
during this period. Once her hemoglobin normalized, she
was re-challenged with ipilimumab and nivolumab. She
developed hemolytic anemia again after administration of
immunotherapy. She was re-treated with similar steroid
regimen. Due to slow response to steroids and concern for
steroid related side effects, rituximab was added at a
weekly dose of 375 mg/m2 for 4 weeks. She responded
well to this treatment and at the time of last follow up her
hemoglobin normalized. Response to treatment is demon-
strated in Fig. 1. Immunotherapy was put on hold again.
During this period, imaging studies showed improvement
in brain lesions and stable disease elsewhere.
Discussion
Melanoma is a highly malignant tumor of skin. It is the
fifth most common tumor in men and seventh in
women in United States [5]. The prognosis of metastatic
melanoma is poor with a 5-year survival of only 15–20%.
There is great progress made in recent years in the man-
agement of advanced melanoma resulting in approval of
several drugs by Food and Drug Administration (FDA).
Ipilimumab and nivolumab are two of the several drugs
recently approved for metastatic melanoma (http://
www.fda.gov/Drugs/InformationOnDrugs/Approved-
Drugs/ucm465274.htm). Ipilimumab is a CTLA-4 inhibi-
tor and nivolumab is a PD-1 inhibitor, both results in
enhanced anti-tumor immune response [6].
Approximately 50% of AIHA cases are idiopathic [7]
but in the remaining cases, underlying inciting factor
can be found. Common etiology includes underlying
malignancy, autoimmune disorders, drugs and infections
[8]. Diagnosis of AIHA is relatively easy given the con-
stellation of laboratory findings of normocytic or macro-
cytic anemia, reticulocytosis, low serum haptoglobin
levels, elevated LDH level, increased indirect bilirubin
level and a positive direct antiglobulin test. Once the
diagnosis is established, it is important to rule out any
secondary causes as managing the underlying cause can
indirectly improve the AIHA, particularly in drug-
induced hemolytic anemia [7]. Initial treatment of AIHA
involves high dose steroids with slow taper. Steroids
work primarily by inducing immunosuppression result-
ing in reduction of autoantibodies production. Rituxi-
mab is usually reserved for refractory and relapsed cases.
Rituximab is a chimeric monoclonal antibody that
causes apoptosis of B-lymphocytes by binding to CD20
positive B-lymphocytes. Depletion of B-lymphocytes lead
to reduction in autoantibodies, inflammatory cytokines
and T-cell activation.
Due to increasing use of immunotherapy, there is
growing number of reports of AIHA related to check-
point inhibitors, primarily anti-PD1 as depicted in
Table 2 [9–13]. Interestingly, no AIHA was reported in
patients who received the combination of ipilimumab
and nivolumab in the medical literature. Our case was
different from reported cases in number of ways: first, it
documents the recurrence of AIHA after re-challenge of
combined immunotherapy drugs; second, unlike the
other cases, we propose rituximab as a treatment choice





Total Bilirubin 1.5 mg/dL
Coombs Test Positive for both anti-Ig
G and anti-complement 3d
Peripheral smear findings Spherocytes and polychromatic
cells
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Table 2 Reported cases of immunotherapy associated AIHA
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Simeone E.
et al. [13]
Ipilimumab 3 Stage III
melanoma
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Fig. 1 Graph for hemoglobin and LDH versus time
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for relapsed and refractory cases of immunotherapy-
induced AIHA; third, none of the other cases reported
AIHA due to combined immunotherapy. It can be
learned from our experience that rituximab can also be
successfully used for relapsed or resistant cases of
immunotherapy induced AIHA. It is unknown which of
the two drugs caused AIHA in our patient, however
both drugs have been reported to be implicated in caus-
ing AIHA as previously described in Table 2. The under-
lying mechanism of immunotherapy-induced hemolytic
anemia is unconfirmed but generally drug induced
AIHA is categorized into drug-independent (via auto-
antibodies) and drug-dependent antibodies causing
immune hemolytic anemia. A drug-dependent antibody
activates a response only while the drug is present. In
contrast drug independent antibodies, are capable of
creating an autoimmune response in the absence of the
offending drug [14]. It is not clearly understood why
autoantibodies production begins but a number of
mechanisms have been proposed including defective
control of IgG auto-reactivity by autologous IgM and
alteration of T-cell function [15–18].
Conclusions
AIHA can be life threatening if not treated promptly. It
is always prudent to exclude any inciting factor, particu-
larly drugs because cessation of the drug is often suffi-
cient to resolve the hemolysis. Immunotherapy agents
have been approved in several solid and hematologic
malignancies [19], therefore, it is important for all health
care professionals caring for cancer patients to recognize
the adverse effects of immunotherapy, especially AIHA
as depicted in our case.
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